Cargando…
Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly se...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310569/ https://www.ncbi.nlm.nih.gov/pubmed/34320413 http://dx.doi.org/10.1016/j.ijid.2021.07.052 |
_version_ | 1783728787465175040 |
---|---|
author | Al Bahrani, Salma Albarrak, Ali Alghamdi, Othman Ali Alghamdi, Mesfer Abdullah Hakami, Fatimah H. Al Abaadi, Asmaa K. Alkhrashi, Sausan A. Alghamdi, Mansour Y. Almershad, Meshael M. Alenazi, Mansour Moklif El Gezery, Mohamed Hany Jebakumar, Arulanantham Zechariah Al-Tawfiq, Jaffar A. |
author_facet | Al Bahrani, Salma Albarrak, Ali Alghamdi, Othman Ali Alghamdi, Mesfer Abdullah Hakami, Fatimah H. Al Abaadi, Asmaa K. Alkhrashi, Sausan A. Alghamdi, Mansour Y. Almershad, Meshael M. Alenazi, Mansour Moklif El Gezery, Mohamed Hany Jebakumar, Arulanantham Zechariah Al-Tawfiq, Jaffar A. |
author_sort | Al Bahrani, Salma |
collection | PubMed |
description | INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. RESULTS: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. CONCLUSION: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period. |
format | Online Article Text |
id | pubmed-8310569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83105692021-07-26 Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia Al Bahrani, Salma Albarrak, Ali Alghamdi, Othman Ali Alghamdi, Mesfer Abdullah Hakami, Fatimah H. Al Abaadi, Asmaa K. Alkhrashi, Sausan A. Alghamdi, Mansour Y. Almershad, Meshael M. Alenazi, Mansour Moklif El Gezery, Mohamed Hany Jebakumar, Arulanantham Zechariah Al-Tawfiq, Jaffar A. Int J Infect Dis Article INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. RESULTS: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. CONCLUSION: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-25 /pmc/articles/PMC8310569/ /pubmed/34320413 http://dx.doi.org/10.1016/j.ijid.2021.07.052 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Al Bahrani, Salma Albarrak, Ali Alghamdi, Othman Ali Alghamdi, Mesfer Abdullah Hakami, Fatimah H. Al Abaadi, Asmaa K. Alkhrashi, Sausan A. Alghamdi, Mansour Y. Almershad, Meshael M. Alenazi, Mansour Moklif El Gezery, Mohamed Hany Jebakumar, Arulanantham Zechariah Al-Tawfiq, Jaffar A. Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title | Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title_full | Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title_fullStr | Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title_full_unstemmed | Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title_short | Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia |
title_sort | safety and reactogenicity of the chadox1 (azd1222) covid-19 vaccine in saudi arabia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310569/ https://www.ncbi.nlm.nih.gov/pubmed/34320413 http://dx.doi.org/10.1016/j.ijid.2021.07.052 |
work_keys_str_mv | AT albahranisalma safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT albarrakali safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alghamdiothmanali safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alghamdimesferabdullah safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT hakamifatimahh safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alabaadiasmaak safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alkhrashisausana safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alghamdimansoury safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT almershadmeshaelm safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT alenazimansourmoklif safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT elgezerymohamedhany safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT jebakumararulananthamzechariah safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia AT altawfiqjaffara safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia |